Company / Cash & Equivalents
Processa Pharmaceuticals, Inc. Cash & Equivalents History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$6.5M
FY2022
5-year range
$2.1K / $16.5M
FY2018-FY2022
Trend
-60.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $3,237 to $7M over the past 6 years.
Based on SEC 10-K filings.
$7M in FY2022.
Improved from $3,237 to $7M over the past 6 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, cash & equivalents decreased 60.6% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $6.5M | -60.6% |
| FY2021 | $16.5M | +509556.5% |
| FY2016 | $3.2K | +54.9% |
| FY2015 | $2.1K | -98.9% |
| FY2014 | $186.9K | -81.7% |
| FY2013 | $1.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026